TUCSON,
Ariz., March 7, 2024 /PRNewswire/ -- Accelerate
Diagnostics, Inc. (NASDAQ: AXDX) announced today that management
will host a conference call on Thursday,
March 28, 2024, at 4:30 p.m. Eastern
Time to review 2023 fourth quarter and full year
results.
To listen to the audio webcast online, visit ir.axdx.com. A
replay of the audio webcast will be available for 30 days.
To listen by phone, dial +1.877.883.0383 and enter the Elite
Entry Number: 7172610. International participants may dial
+1.412.902.6506. Please dial in 10-15 minutes prior to the start of
the conference.
A replay of the call will be available by telephone at
+1.877.344.7529 (U.S.) or +1.412.317.0088 (International) using the
replay code 7585609 until April 18, 2024.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. is an in vitro diagnostics company
dedicated to providing solutions for the global challenges of
antibiotic resistance and sepsis. The Accelerate Pheno® system and
Accelerate PhenoTest® BC kit combine several technologies aimed at
reducing the time clinicians must wait to determine the most
optimal antibiotic therapy for deadly infections. The FDA cleared
system and kit fully automate the sample preparation steps to
report phenotypic antibiotic susceptibility results in
approximately 7 hours direct from positive blood cultures. Recent
external studies indicate the solution offers results 1-2 days
faster than existing methods, enabling clinicians to optimize
antibiotic selection and dosage specific to the individual patient
days earlier.
The "ACCELERATE DIAGNOSTICS" and "ACCELERATE PHENO" and
"ACCELERATE PHENO TEST" and "ACCELERATE WAVE" and diamond shaped
logos and marks are registered trademarks of Accelerate
Diagnostics, Inc.
For more information about the company, its products and
technology, or recent publications, visit axdx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/accelerate-diagnostics-scheduled-call-to-review-2023-fourth-quarter-and-full-year-results-302081894.html
SOURCE Accelerate Diagnostics, Inc.